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Background-—Worsening renal function (WRF) is associated with adverse outcomes in patients with heart failure. We investigated
the predictors and prognostic value of WRF during admission, in patients with preserved ejection fraction (HFpEF) versus those
with reduced ejection fraction (HFrEF).
Methods and Results-—A total of 5625 patients were enrolled in the KorAHF (Korean Acute Heart Failure) registry. WRF was deﬁned
as an absolute increase in creatinine of ≥0.3 mg/dL. Transient WRF was deﬁned as recovery of creatinine at discharge, whereas
persistent WRF was indicated by a nonrecovered creatinine level. HFpEF and HFrEF were deﬁned as a left ventricle ejection fraction
≥50% and ≤40%, respectively. Among the total population, WRF occurred in 3101 patients (55.1%). By heart failure subgroup, WRF
occurred more frequently in HFrEF (57.0% versus 51.3%; P<0.001 in HFrEF and HFpEF). Prevalence of WRF increased as creatinine
clearance decreased in both heart failure subgroups. Among various predictors of WRF, chronic renal failure was the strongest
predictor. WRFwas an independent predictor of adverse in-hospital outcomes (HFrEF: odds ratio; 2.75; 95% conﬁdence interval, 1.50–
5.02; P=0.001; HFpEF: odds ratio, 9.48; 95% conﬁdence interval, 1.19–75.89; P=0.034) and 1-year mortality (HFrEF: hazard ratio,
1.41; 95% conﬁdence interval, 1.12–1.78; P=0.004 versus HFpEF: hazard ratio, 1.72; 95% conﬁdence interval, 1.23–2.42; P=0.002).
Transient WRF was a risk factor for 1-year mortality, whereas persistent WRF had no additive risk compared to transient WRF.
Conclusions-—In patients with acute heart failure patients, WRF is an independent predictor of adverse in-hospital and follow-up
outcomes in both HFrEF and HFpEF, though with a different effect size.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT01389843. ( J Am Heart Assoc. 2018;7:
e007910. DOI: 10.1161/JAHA.117.007910.)
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W orsening renal function (WRF) represents a deteriora-tion of renal function over time, and it is associated
with worse outcomes in patients with acute and chronic heart
failure (HF).1,2 Previous reports have shown that WRF is
associated with death and HF hospitalization.3,4 Bidirectional
interactions exist between heart disease and kidney disease,
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referred to as cardiorenal syndrome,5 and neurohumoral
maladaptation and decreased renal perfusion are 2 of the
discussed mechanisms.6
Among patients with HF, up to 50% of the patients have
normal or near normal left ventricular ejection fraction
(LVEF), known as HF with preserved ejection fraction
(HFpEF).7 They have a prognosis similar to those with HF
with reduced ejection fraction (HFrEF).8 Whether HFpEF and
HFrEF represent distinct forms of HF, or exist as part of an
“HF spectrum,” has yet to be established.9 However, the
different patterns of chamber remodeling and disparate
responses to medical therapies suggest that they are 2
discrete disease processes. Furthermore, patients with HFrEF
have higher B-type natriuretic peptide (BNP) levels than
patients with HFpEF, which suggests that they have a higher
degree of neurohumoral activity.10,11 This prompts consider-
ation of whether the clinical signiﬁcance of WRF may be
dependent on HF type.
Until now, the predictors of WRF and prognostic value of
WRF on outcomes have not been well established in either
type of HF. Therefore, in this study, we sought to evaluate the
inﬂuence of WRF in acute HF patients according to HF type.
Methods
Data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure, because the
data are protected by the Korean Ministry of Health and
Welfare.
Study Design and Population
The KorAHF (Korean Acute Heart Failure) registry was a
prospective, multicenter cohort study that was designed to
describe patient characteristics, current treatments, and
short- and long-term patient outcomes among Korean
patients with acute HF. A total of 5625 patients were enrolled
from the KorAHF registry from March 2011 to February 2014
at 10 tertiary centers. Detailed information on the study
design and results has been previously reported else-
where.4,12 Brieﬂy, patients with signs or symptoms of HF
and either lung congestion, objective ﬁndings of left
Table 1. Etiology of the Total Population and HFrEF, HFpEF
Subgroups
Etiology
Total
Population HFrEF HFpEF P Value
Ischemic heart
disease
2113 (37.6) 1381 (43.0) 295 (21.7) <0.001
Valvular heart
disease
804 (14.3) 232 (7.5) 405 (31.3) <0.001
Congenital heart
disease
63 (1.1) 15 (0.5) 28 (2.2) <0.001
Cardiomyopathy 1159 (20.6) 933 (30.0) 82 (6.3) <0.001
Hypertensive 222 (3.9) 91 (2.9) 82 (6.3) <0.001
Myositis 78 (1.4) 49 (1.6) 13 (1.0) 0.141
Infiltrative
disease
70 (1.2) 23 (0.7) 26 (2.0) <0.001
Tachycardia
related
600 (10.7) 250 (8.1) 182 (14.1) <0.001
Thyroid related 30 (0.5) 12 (0.4) 11 (0.8) 0.052
Toxic related 59 (1.0) 44 (1.4) 3 (0.2) <0.001
Unknown 178 (4.0) 109 (3.5) 69 (5.3) 0.005
Others 152 (3.5) 30 (1.0) 122 (9.4) <0.001
Values are expressed in n (%). HFpEF indicates heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction.
Clinical Perspective
What Is New?
• From a prospective, multicenter cohort, the KorAHF (Korean
Acute Heart Failure) registry, worsening renal function
(WRF) occurred in 55.1%, and patients with reduced ejection
fraction had a higher rate of WRF than did the patients with
preserved ejection fraction (HFpEF).
• WRF was an independent predictor of adverse in-hospital
outcomes (deﬁned as all-cause mortality or aggravation of
heart failure during hospitalization) in both patients with
reduced ejection fraction and HFpEF, whereas the effect
size of WRF was 3-fold larger in HFpEF.
• WRF was associated with 3-month and 1-year mortality in
both patients with reduced ejection fraction and HFpEF.
Regarding the degree of WRF (transient WRF and persistent
WRF), transient WRF was an independent risk factor for
long-term mortality, whereas persistent WRF had no additive
risk compared with transient WRF.
What Are the Clinical Implications?
• Our results reﬂect the rate of WRF in real-world heart failure
patients; more than one half of acute heart failure patients
experienced WRF, which was associated with adverse
in-hospital outcomes and adverse 1-year mortality.
• We compared the effect size of WRF for adverse outcomes
in acute heart failure patients with patients with reduced
ejection fraction versus HFpEF, showing that WRF had a
larger effect size on adverse outcomes in HFpEF patients.
• Patients with transient WRF had a higher risk for 1-year
mortality compared with those without WRF, whereas
persistent WRF was not a risk factor compared with
transient WRF.
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ventricular systolic dysfunction, or structural heart disease
were eligible for the study. Detailed variables were collected
at admission, and events including all-cause mortality,
mortality from HF aggravation, and rehospitalization for HF
aggravation were recorded after discharge. Follow-up data
were collected from patients by the attending physician at
30 days and 3, 6, 12, 24, 36, 48, and 60 months after
discharge. The study is currently continuing follow-up.
The study protocol was approved by the ethics committee
at each participating center and was conducted according to
the principles of the Declaration of Helsinki. All patients
provided written informed consent for participation in the
registry.
Study End Points and Deﬁnitions
Clinical outcomes included adverse in-hospital outcomes
(deﬁned as all-cause mortality or aggravation of HF during
hospitalization) and all-cause mortality during follow-up. All-
cause mortality was analyzed by short-term (3-month) and
long-term (1-year) events. Despite the absence of expert
consensus in terms of the deﬁnition of WRF, WRF was deﬁned
as an absolute increase in creatinine of 0.3 mg/dL or more,
as per previous studies.13 In the present study, WRF was
limited to those occurring during admission. Transient WRF
was deﬁned as a recovery of creatinine level at discharge, by
more than 0.3 mg/dL compared with the peak level during
admission. Persistent WRF was deﬁned as a nonrecovered
creatinine level. Stages of glomerular ﬁltration rate (GFR) were
deﬁned according to the Kidney Disease Outcomes Quality
Table 2. Demographic and Laboratory Characteristics
Between HFpEF and HFrEF Subgroups
HFrEF HFpEF P Value
Sex, male 1872 (60.3%) 496 (38.3%) <0.001
Age, y 66.314.7 72.013.5 <0.001
BMI, kg/m2 23.13.8 23.84.0 <0.001
LVEF, % 27.07.7 59.56.6 <0.001
Risk factors
Hypertension, n (%) 1832 (59.0) 865 (66.8) <0.001
DM, n (%) 1297 (41.8) 435 (33.6) <0.001
Smoking, %* 21.3/22.5/56.2 11.9/16.5/7106 <0.001
Previous MI, n (%) 590 (19.0) 112 (8.6) <0.001
Previous PCI, n (%) 55 (18.2) 151 (11.7) <0.001
Previous CABG, n (%) 181 (5.8) 34 (2.6) <0.001
COPD, n (%) 328 (10.6) 174 (13.4) 0.006
CRF, n (%) 449 (14.5) 150 (11.6) 0.011
Previous CVA, n (%) 442 (14.2) 206 (15.9) 0.154
Alcohol, %† 7.5/35.0/57.5 5.3/25.6/69.2 <0.001
Valve disease, n (%) 279 (9.0) 348 (26.9) <0.001
Arrythmia, n (%) 898 (28.9) 531 (41.0) <0.001
NYHA at admission, % 13.7/37.0/49.3 18.5/37.5/43.9 <0.001
Initial SBP, mm Hg 12829 13630 <0.001
Initial DBP, mm Hg 7919 7718 <0.001
Initial HR 9525 8626 <0.001
Laboratory analysis
WBC, 109/L 87704220 81603500 <0.001
Hb, g/dL 12.72.3 12.02.2 <0.001
Platelet, 109/L 21692 20289 <0.001
Total cholesterol,
mg/dL
15343 14943 0.020
Triglyceride, mg/dL 9958 10161 0.556
HDL, mg/dL 4114 4213 0.165
LDL, mg/dL 9637 9037 0.001
Na, mEq/L 1375 1385 0.697
Uric acid, mg/dL 7.33.1 6.72.6 <0.001
BUN, mg/dL 26.716.8 24.514.9 <0.001
Creatinine, mg/dL 1.511.47 1.281.07 <0.001
Glucose, mg/dL 15878 14568 <0.001
CRP, mg/L 2.254.11 2.394.28 0.328
BNP, pg/mL 16001410 810850 <0.001
NTproBNP, pg/mL 10 69011 700 52806870 <0.001
BMI indicates body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen;
CABG, coronary artery bypass graft surgery; COPD, chronic obstructive pulmonary
disease; CRP, C-reactive protein; CRF, chronic renal failure; CVA, cerebrovascular
accident; DBP, diastolic blood pressure; DM, diabetes mellitus; Hb, hemoglobin; HDL,
high-density lipoprotein; HFpEF, heart failure with preserved ejection fraction; HFrEF,
heart failure with reduced ejection fraction; HR, heart rate; LDL, low-density lipoprotein;
LVEF, left ventricular ejection fraction; MI, myocardial infarction; Na, natrium; NTproBNP,
N-terminal pro-brain-type natriuretic peptide; PCI, percutaneous coronary intervention;
SBP, systolic blood pressure; WBC, white blood cell.
*Smoking: current smoker/ex-smoker/never smoker.
†
Alcohol: heavy drinker/social drinker/never drinker.
Figure 1. Prevalence of WRF and persistent WRF. WRF occurred
in 55.1% of the total population, among which 38.1% showed
persistent WRF. In subgroups of HFrEF and HFpEF, WRF and
persistent WRF were more common in the HFrEF group.
Abbreviations: HFrEF indicates heart failure with reduced ejection
fraction; HFpEF, heart failure with preserved ejection fraction;
WRF, worsening renal function.
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Table 3. Demographic and Laboratory Characteristics According to the Severity of WRF
No WRF
(n=2520)
Transient
WRF (n=1919)
Persistent
WRF (n=1182) P Value
Sex, male 1270 (50.4%) 1046 (54.5%) 675 (57.1%) <0.001
Age, y 67.414.8 69.014.6 70.013.4 <0.001
BMI, kg/m2 23.63.9 23.13.9 23.13.7 <0.001
LVEF, % 38.815.7 37.016.0 36.314.8 <0.001
Risk factors
Hypertension, n (%) 1461 (58.0) 1188 (61.9) 845 (71.5) <0.001
DM, n (%) 800 (31.7) 833 (43.4) 614 (51.9) <0.001
Smoking, %* 17.8/19.4/62.8 17.8/21.8/60.3 17.0/22.9/60.1 0.107
Previous MI, n (%) 355 (14.1) 327 (17.0) 235 (19.9) <0.001
Previous PCI, n (%) 371 (14.7) 321 (16.7) 251 (21.3) <0.001
Previous CABG, n (%) 102 (4.1) 116 (6.0) 72 (6.1) 0.003
COPD, n (%) 273 (10.8) 220 (11.5) 140 (11.8) 0.627
CRF, n (%) 115 (4.6) 312 (16.3) 378 (32.0) <0.001
Previous CVA, n (%) 340 (13.5) 318 (16.6) 194 (16.4) 0.007
Alcohol, %† 6.8/33.3/59.9 6.8/29.7/63.5 5.8/31.9/62.4 0.075
Valve disease, n (%) 352 (14.0) 296 (15.4) 160 (13.5) 0.252
Arrhythmia, n (%) 827 (32.8) 674 (35.1) 369 (31.2) 0.064
NYHA II/III/IV at admission, % 19.6/41.8/38.6 13.0/34.2/52.8 9.2/30.8/60.0 <0.001
Initial SBP, mm Hg 13228 12832 13433 <0.001
Initial DBP, mm Hg 8018 7619 7920 <0.001
Initial HR 9226 9327 9325 0.054
Laboratory analysis
WBC, 109/L 78503150 94004440 92504840 <0.001
Hb, g/dL 12.92.1 12.22.4 11.62.3 <0.001
Platelet, 109/L 21379 21198 20595 0.001
Total cholesterol, mg/dL 15642 14744 14944 <0.001
Triglyceride, mg/dL 10060 10061 9754 0.247
HDL, mg/dL 4414 3914 4014 <0.001
LDL, mg/dL 9636 9138 9339 0.066
Na, mEq/L 1384 1375 1375 <0.001
Uric acid, mg/dL 6.32.5 7.73.1 7.42.9 <0.001
BUN, mg/dL 19.28.4 31.118.0 33.320.4 <0.001
Creatinine, mg/dL 0.990.53 1.631.32 2.312.38 <0.001
Glucose, mg/dL 14262 16484 17088 <0.001
CRP, mg/L 1.503.07 2.894.77 3.245.02 <0.001
BNP, pg/mL 980890 15101410 18501620 <0.001
NTproBNP, pg/mL 55606670 11 00011 100 13 71014 050 <0.001
During Adm.
Mech. Ventil., n (%) 63 (2.5) 453 (23.6) 346 (29.3) <0.001
Transfusion, n (%) 140 (5.6) 599 (31.2) 464 (39.3) <0.001
Intravascular diuretics, n (%) 1671 (66.3) 1579 (82.3) 963 (81.5) <0.001
Continued
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Initiative (KDOQI) Clinical Practice Guidelines for chronic renal
failure (CRF). According to GFR at admission, GFR ≥60 mL/
min per 1.73 m2, GFR 30 to 59 mL/min per 1.73 m2, and
GFR <30 mL/min per 1.73 m2 were deﬁned as “mildly,”
“moderately,” and as “severely decreased GFR,” respectively.
HFpEF and HFrEF were deﬁned as LVEF ≥50% and LVEF≤40%,
respectively.7 Patients with a 40% <LVEF <50% were excluded
from the study.
Statistical Analyses
All variables and outcome analyses were based on WRF. Data
are presented as numbers and frequencies for categorical
variables and as meansSD for continuous variables. For
comparison among groups, the v2 test (or Fisher’s exact test
when any expected count was <5 for a 292 table) for
categorical variables and the unpaired Student t test or 1-way
analysis of variance for continuous variables were applied.
To estimate the predictors of WRF, and to predict the
independent effect of WRF on adverse in-hospital outcomes,
we used the multivariable logistic regression model using a
step-wise algorithm. Variables found to be statistically
signiﬁcant in the univariate analysis were included in the
multivariable model, excluding variables that were closely
related to other clinical variables. As a result, variables such
as sex, old age, body mass index, hypertension, diabetes
mellitus, CRF, previous myocardial infarction, New York Heart
Association grade, LVEF (HFrEF or HFpEF), laboratory results
at admission (ie, white blood cell count, hemoglobin, sodium,
BNP (or N-terminal pro-brain-type natriuretic peptide,
C-reactive protein levels), and intravenous medications during
admission (ie, diuretics, inotropes, and vasodilators) were
included in the model. Assumptions of the logistic regression
model (eg, dichotomous dependent variable, independence in
each observation, linear relationship between continuous
independent variables and the logit transformation of the
Table 3. Continued
No WRF
(n=2520)
Transient
WRF (n=1919)
Persistent
WRF (n=1182) P Value
Intravascular inotropics, n (%) 361 (14.3) 849 (44.2) 539 (45.6) <0.001
Intravascular vasodilators, n (%) 871 (34.6) 848 (44.2) 582 (49.2) <0.001
BMI indicates body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; CRP, C-reactive
protein; DBP, diastolic blood pressure; DM, diabetes mellitus; HDL, high-density lipoprotein cholesterol; HR, heart rate; LDL, low-density lipoprotein cholesterol; LVEF, left ventricle ejection
fraction; MI, myocardial infarction; NTproBNP, N-terminal pro-brain-type natriuretic peptide; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; WBC, white blood cell.
*Smoking: current smoker/ex-smoker/never smoker.
†
Alcohol: heavy drinker/social drinker/never drinker.
Figure 2. Prevalence of WRF by CRF stage. Prevalence of WRF increased along with the decrease of initial
GFR at admission. Dark wine color represents persistent WRF, and gray color represents transient WRF.
Both transient and persistent WRF increased as GFR grade decreased, in the (A) total study population,
(B) HFrEF group, and (C) HFpEF group. GFR indiactes glomerular ﬁltration rate; HFpEF, heart failure with
preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; WRF, worsening renal
function.
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dependent variable, and multicollinearity) were tested. The
Cox and Snell R Square, Nagelkerke R square, and Hosmer-
Lemeshow goodness-of-ﬁt test were used to evaluate model
calibration. A 2-sided probability value <0.05 was considered
to estimate statistically signiﬁcant differences. Statistical
tests were performed using SPSS (v22.0; IMB Corporation,
Armonk, NY) and Stata (version 10; 2007; StataCorp LP,
College Station, TX).
Results
A total of 5625 patients were enrolled in the KorAHF registry.
Mean age was 68.514.5 years, with a mean LVEF of
37.715.6%, and the most common etiology of HF was
ischemic heart disease (2113 patients [37.6%]; Table 1). By
deﬁnition, 3105 patients (55.2%) had HFrEF, 1295 (23.0%)
had HFpEF, and the remaining patients had HF with mid-range
ejection fraction (40% <LVEF <50%). Characteristics of
patients with HFpEF and HFrEF at admission (Table 2)
showed that the 2 groups had distinct characteristics.
WRF and Risk Factors
At admission, creatinine level was 1.491.47 mg/dL, which
peaked to 1.831.78 mg/dL during hospitalization and
decreased to 1.401.36 mg/dL before discharge. WRF
during admission occurred in 3101 patients (55.1%), of which
980 (17.4%) had a creatinine increase greater than 1.0 mg/
dL. Patients with HFrEF had a higher rate of WRF than did
those with HFpEF (56.9% versus 50.3%; P<0.001). Among
patients with WRF, 1919 (61.9%) showed transient WRF; rates
of persistent WRF were higher in patients with HFrEF (38.7%
versus 34.3%; P=0.045; Figure 1).
Characteristics of the “no WRF,” “transient WRF,” and
“persistent WRF” groups at admission are shown in Table 3.
Patients with persistent WRF were more “sick” with a
greater number of risk factors, compared with those in the
“no WRF” and “transient WRF” groups. Prevalence of WRF
increased as GFR decreased, and among the types of WRF,
persistent WRF was shown to increase gradually along with
grade of GFR decrease (Figure 2A). This trend was also
present in both HFrEF and HFpEF subgroups (Figure 2B and
2C).
Among various risk factors identiﬁed for WRF, CRF and
usage of inotropes were the strongest predictors of WRF
Table 4. Multivariate Analysis for Predictors of WRF
Factor
Whole HFrEF HFpEF
OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value
Sex, female 1.26 1.05 to 1.52 0.015
BMI <25 kg/m2 1.20 1.00 to 1.45 0.049 1.26 1.01 to 1.58 0.041
Hypertension 1.22 1.02 to 1.45 0.030 1.27 1.03 to 1.56 0.028
Diabetes mellitus 1.30 1.09 to 1.55 0.003 1.26 1.03 to 1.55 0.027
CRF 4.62 3.36 to 6.34 <0.001 5.24 3.55 to 7.75 <0.001 2.97 1.69 to 5.23 <0.001
Na <135 mmol/L 1.78 1.44 to 2.19 <0.001 1.64 1.28 to 2.11 <0.001 2.20 1.49 to 3.24 <0.001
Hb <12 g/dL 1.63 1.36 to 1.96 <0.001 1.73 1.38 to 2.17 <0.001 1.52 1.10 to 2.09 0.011
High BNP or NTproBNP 1.68 1.41 to 2.00 <0.001 1.52 1.24 to 1.87 <0.001 2.17 1.52 to 3.09 <0.001
Uric acid >7 mg/dL 2.28 1.92 to 2.70 <0.001 2.32 1.90 to 2.84 <0.001 2.54 1.83 to 3.52 <0.001
CRP >0.5 mg/dL 1.63 1.36 to 1.95 <0.001 1.73 1.39 to 2.16 <0.001 1.43 1.02 to 1.99 0.037
Diuretic usage 1.55 1.26 to 1.90 <0.001 1.32 1.03 to 1.69 0.027 2.43 1.67 to 3.53 <0.001
Inotropic usage 4.88 4.03 to 5.92 <0.001 4.32 3.48 to 5.36 <0.001 8.65 5.45 to 13.74 <0.001
Vasodilator usage 1.30 1.10 to 1.54 0.001 1.45 1.19 to 1.78 <0.001
HFrEF (vs HFpEF) 0.84 0.70 to 1.02 0.077
BMI indicates body mass index; BNP, brain natriuretic peptide; CI, conﬁdence interval; CRF, chronic renal failure; CRP, C-reactive protein; HFpEF, heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction; NTproBNP, N-terminal pro-brain-type natriuretic peptide; WBC, white blood cell; WRF, worsening renal function.
Table 5. Adverse in-Hospital Clinical Outcomes
No WRF WRF P Value
Total population 24/2520 (1.0%) 268/3101 (8.6%) <0.001
HFrEF 16/1339 (1.2%) 149/1765 (8.4%) <0.001
HFpEF 3/643 (0.5%) 36/651 (5.5%) <0.001
HFpEF indicates heart failure with preserved ejection fraction; HFrEF, heart failure with
reduced ejection fraction; WRF, worsening renal function.
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(Table 4). When the population was divided into patients with
HFrEF and those with HFpEF, the 2 populations showed
different risk-factor proﬁles; CRF, hyponatremia, anemia, high
BNP or N-terminal pro-brain-type natriuretic peptide, high
C-reactive protein, high uric acid levels, and usage of diuretics
and inotropes were common risk factors, whereas low body
mass index, hypertension, diabetes mellitus, and vasodilator
usage during admission were predictors of WRF in patients
with HFrEF only.
Adverse In-Hospital Outcomes
Among the entire study population, the mean hospitalization
duration was 14.017.6 days; overall, it was longer in
patients with HFrEF than in those with HFpEF (14.817.7
versus 12.916.9 days; P=0.001). It was also longer in
patients with WRF than in those without WRF (7.95.2 versus
18.922.0 days; P<0.001).
Adverse in-hospital outcomes occurred in 292 patients
(5.2%). Patients with WRF during admission had a higher
number of in-hospital outcomes (24/2520 [1.0%] versus 268/
3101 [8.6%], P<0.001 in WRF () and WRF (+), respectively)
in both the total population and the subgroups of HFrEF and
HFpEF (Table 5). In the multivariate analysis, WRF was
independently associated with adverse in-hospital outcomes
in the total patient population (odds ratio, 3.18; 95%
conﬁdence interval [CI], 1.78–5.67; P<0.001), as well as in
the subgroups of HFrEF (odds ratio, 2.73; 95% CI, 1.48–5.01;
P=0.001) and HFpEF (odds ratio, 8.53; 95% CI, 1.06–68.48;
P=0.044; Table 6).
Short- and Long-Term Follow-up Mortality by WRF
During the 1-year follow-up duration, 970 patients (17.2%)
died. Regarding short-term (3-month) and long-term (1-year)
mortality, mortality increased with severity of WRF in the total
population, and in the HFrEF and HFpEF subgroups (Figure 3;
Table 7). Using a Cox proportional hazard model, WRF was
independently associated with short-term mortality (hazard
ratio [HR], 1.66; 95% CI, 1.22–2.25; P=0.001) and long-term
mortality (HR, 1.39; 95% CI, 1.14–1.69; P=0.001). When
stratiﬁed according to HF type, WRF remained a signiﬁcant
risk factor in both the HFrEF and HFpEF subgroups (Table 8).
Regarding the association with 3- and 12-month mortality,
WRF has a larger effect size in HFpEF compared with HFrEF
(3-month mortality: HR 1.59 for HFrEF and HR 1.86 for HFpEF;
12-month mortality: HR 1.35 for HFrEF and HR 1.54 for
HFpEF; Table 8).
We also analyzed whether transient WRF and persistent
WRF had different effects on long-term mortality. Transient
WRF, when compared with the “no WRF” group, was a
signiﬁcantly associated with long-term mortality after adjust-
ing for other risk factors (Table 9). However, persistent WRF
was not associated with mortality, when compared with
transient WRF.
Discussion
In the current study, we determined the predictors of WRF
during admission and examined the prognostic value of WRF
for in-hospital and short- and long-term outcomes according
to the HF type (ie, HFrEF versus HFpEF) and severity of WRF
(ie, transient versus persistent WRF). As expected, patients
with more-severe WRF had more cardiac risk factors at
admission. Among the various predictors of WRF, CRF and
usage of inotropes were the predictors with the largest odds
ratio. Interestingly, although WRF was a signiﬁcant risk factor
in both HFpEF and HFrEF, the effect size on in-hospital
outcomes was 3-fold larger in HFpEF. Finally, WRF was
associated with short- and long-term mortality in both HFrEF
Table 6. Multivariate Analysis for Predictors of Adverse in-Hospital Outcomes
Total HFrEF HFpEF
OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value
WRF 3.18 1.78 to 5.67 <0.001 2.73 1.48 to 5.01 0.001 8.53 1.06 to 68.48 0.044
Age >70 y 2.08 1.40 to 3.10 <0.001 2.29 1.48 to 3.54 <0.001 NA
Arrhythmia 1.72 1.13 to 2.62 0.011 2.05 1.25 to 3.37 0.004 NA
CRP >0.5 mg/dL 1.66 1.16 to 2.37 0.005 1.60 1.07 to 2.37 0.021 NA
High BNP or NTproBNP 1.61 1.07 to 2.43 0.022 1.61 1.01 to 2.57 0.044 NA
Inotropics usage 6.74 4.39 to 10.33 <0.001 6.36 3.95 to 10.26 <0.001 8.45 3.16 to 22.63 <0.001
HFrEF (vs HFpEF) 1.14 0.71 to 1.83 0.590 NA NA
BNP indicates brain natriuretic peptide; CI, conﬁdence interval; CRF, chronic renal failure; CRP, C-reactive protein; Hb, hemoglobin; HFpEF, heart failure with preserved ejection fraction;
HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; Na, sodium; NA, not applicable; NTproBNP, N-terminal pro-brain-type natriuretic peptide; OR, odds ratio; UA, uric acid;
WRF, worsening renal function.
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and HFpEF, and the mortality rate increased alongside the
degree of WRF, from no WRF, to transient WRF, and then to
persistent WRF. After adjustment, transient WRF was an
independent risk factor for long-term mortality, whereas
persistent WRF had no additive risk compared to transient
WRF.
Predictors of WRF in HFrEF and HFpEF
There exists a close neurohumoral interaction between the
heart and kidney.5,6 Moreover, HFrEF and HFpEF have distinct
anatomical contributors to the differences in hemodynamic
and neurohumoral effects; speciﬁcally, patients with HFrEF
have higher BNP levels than do HFpEF patients in this study
and others.11 In this study, prevalence of WRF was higher in
patients with HFrEF than in those with HFpEF, and HFrEF was
associated with a 1.19-fold increased risk for WRF. A
signiﬁcant correlation between WRF and BNP levels was also
found (data not shown).
Regarding the predictors of WRF, most predictors of WRF
were similar in HFrEF and HFpEF; among them, CRF and
inotropic usage were shown to have the greatest impact.
Patients with preexisting renal dysfunction are more vulner-
able to diverse insults, which is demonstrated by the
increased prevalence of WRF and persistent WRF in patients
with more-decreased initial GFR. Furthermore, use of inotropic
agents indicates a hemodynamic instability that may cause
renal hypoperfusion.
WRF as a Risk Factor in HF
Deﬁned as reduction in glomerular ﬁltration, WRF has been
associated with adverse outcomes in patients with HF in
previous studies. Pimentel et al reported that patients with
WRF had a signiﬁcantly increased risk of all-cause death and
hospital admission in chronic HF patients.14 Damman et al
showed that WRF was associated with lower survival and
more morbidity in acute HF patients, from the COACH
(Coordinating Study Evaluating Outcome of Advising and
Counseling in Heart Failure) study.15 Additionally, a meta-
analysis by Damman et al including 45 000 patients from 28
studies showed that WRF was associated with mortality
whereas CRF, hypertension, diabetes mellitus, age, and
Figure 3. Survival curve of the total population by the severity
of WRF. Short-term (3-month) and long-term (1-year) mortality
increased with severity of WRF in (A) the total study population,
(B) the HFrEF group, and (C) the HFpEF group. HFpEF indicates
heart failure with preserved ejection fraction; HFrEF, heart failure
with reduced ejection fraction; WRF, worsening renal function.
Table 7. 1-Year Follow-up Clinical Outcomes
No WRF
Transient
WRF
Persistent
WRF P Value
3-month mortality
Total population 109 (4.3) 185 (10.0) 145 (14.5) <0.001
HFrEF 69 (5.2) 106 (10.2) 89 (15.3) <0.001
HFpEF 24 (3.7) 38 (9.0) 28 (14.6) <0.001
1-year mortality
Total population 298 (11.9) 407 (22.0) 265 (26.6) <0.001
HFrEF 161 (12.1) 224 (21.5) 157 (26.9) <0.001
HFpEF 74 (11.5) 93 (21.9) 48 (25.0) <0.001
Values are expressed in n (%). HFpEF indicates heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction; WRF, worsening renal
function.
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diuretic use were signiﬁcant predictors for occurrence of
WRF.4 Although these studies show similar results, the
precise mechanism by which WRF exerts adverse prognostic
effects remains unclear. Testani et al explained that several
hypothetical mechanisms, including inﬂammation, oxidative
stress, or induction of apoptosis by uremic toxins, may
partially contribute to the adverse effect of WRF.16 However,
this study also claimed that it is still uncertain whether WRF is
a mediator or marker for adverse outcomes.
In this study, magnitude of effect size for WRF decreased
from 3.18, to 1.66, to 1.39 for adverse in-hospital outcomes,
and 3- and 12-month mortality, respectively. Because we
deﬁned WRF as an in-hospital event, this decrease seems
understandable. Although the exact mechanisms are still not
well deﬁned, there are a couple of proposed explanations for
the role of WRF as a predictor of adverse outcomes. Renal
dysfunction may reﬂect impaired hemodynamic status that is
related to severity of the underlying HF, reﬂected by the high
HR for in-hospital outcomes.17 Furthermore, renal dysfunction
might be a marker of general vascular disease, such as
severity of atherosclerosis in both the kidney and heart, which
explains the long-term outcomes with a smaller impact size.18
Impact of WRF on Outcomes in HFrEF Versus
HFpEF
Whereas WRF was an independent risk factor for all analyzed
outcomes, the effect size was larger in HFpEF; particularly for
in-hospital outcomes, effect size was 3-fold larger in HFpEF.
No current studies have compared the effect size of WRF in
HF subtypes, whereas a previous study showed that WRF was
a predictor of adverse events in HFpEF.19
Regarding the distinct pathophysiology of HFpEF and
HFrEF, it is known that unfavorable volume distribution is a
more-frequent cause of acute decompensation in HFpEF,
rather than absolute volume overload.20 Therefore, WRF in
HFpEF may reﬂect a relative hypovolemic status with impaired
ﬂuid reﬁlling from the extravascular space to the plasma,
Table 8. Multivariate Analysis for Predictors of All-Cause Mortality During Follow-up
Total HFrEF HFpEF
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
3-month mortality
WRF 1.66 1.22 to 2.25 0.001 1.59 1.10 to 2.29 0.013 1.86 1.06 to 3.27 0.031
Age >70 y 2.46 1.81 to 3.35 <0.001 2.50 1.77 to 3.55 <0.001 2.36 1.22 to 4.60 0.011
Female sex 1.37 1.04 to 1.80 0.028 NA NA
BMI <25 kg/m2 1.69 1.21 to 2.36 0.002 1.73 1.14 to 2.63 0.010 NA
Hb <12 g/dL 1.30 0.99 to 1.70 0.062 1.41 1.02 to 1.95 0.038 NA
Na <135 mmol/L 1.67 1.28 to 2.18 <0.001 1.87 1.37 to 2.54 <0.001 NA
UA >7 mg/dL 1.34 1.04 to 1.74 0.024 NA 1.86 1.14 to 3.03 0.013
CRP >0.5 mg/dL 1.46 1.13 to 1.89 0.004 1.43 1.06 to 1.94 0.020 1.63 1.00 to 2.64 0.049
High BNP or NTproBNP 1.76 1.32 to 2.36 <0.001 1.95 1.35 to 2.84 <0.001 NA
12-month mortality
WRF 1.39 1.14 to 1.69 0.001 1.35 1.06 to 1.71 0.014 1.54 1.08 to 2.18 0.016
Age >70 y 2.20 1.80 to 2.69 <0.001 2.30 1.83 to 2.90 <0.001 1.95 1.28 to 2.98 0.002
Female sex 1.29 1.07 to 1.55 0.007 NA NA
BMI <25 kg/m2 1.47 1.20 to 1.82 <0.001 1.31 1.02 to 1.68 0.038 1.94 1.33 to 2.84 0.001
Diabetes mellitus 1.18 1.00 to 1.41 0.053 1.28 1.04 to 1.58 0.022 NA
CRF 1.36 1.10 to 1.69 0.005 1.43 1.11 to 1.84 0.006 NA
Hb <12 g/dL 1.43 1.19 to 1.73 <0.001 1.46 1.17 to 1.83 0.001 NA
Na <135 mmol/L 1.64 1.37 to 1.96 <0.001 1.73 1.39 to 2.14 <0.001 1.42 1.01 to 2.00 0.047
UA >7 mg/dL 1.20 1.01 to 1.43 0.036 NA 1.57 1.15 to 2.16 0.005
CRP >0.5 mg/dL 1.32 1.11 to 1.56 0.002 1.34 1.09 to 1.65 0.005 NA
High BNP or NTproBNP 1.49 1.23 to 1.79 <0.001 1.68 1.33 to 2.14 <0.001 NA
BNP indicates brain natriuretic peptide; CI, conﬁdence interval; CRF, chronic renal failure; CRP, C-reactive protein; Hb, hemoglobin; HFpEF, heart failure with preserved ejection fraction;
HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; Na, sodium; NA, not applicable; NTproBNP, N-terminal pro-brain-type natriuretic peptide; OR, odds ratio; UA, uric acid;
WRF, worsening renal function.
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which can aggravate both renal and cardiac function. In
contrast, patients with HFrEF experience absolute volume
overload. WRF in HFrEF may develop during decongestion
therapy with diuretics, which can temporarily reduce low
effective circulating volume. This could account for the higher
proportion of transient WRF in the HFrEF group in our
population. Moreover, WRF in HFpEF could be more strongly
associated with adverse outcomes compared with HFrEF.
However, this can only partially explain the larger effect of WRF
in HFpEF, attributed to the complex pathophysiology of WRF.
The other independent predictors of mortality in the HFrEF
subgroup were closely identical to those of the total HF
population, whereas the HFpEF subgroup showed a smaller
number of predictors. HFrEF seemed to be more multifactorial
compared with HFpEF, and WRF seemed to play a larger role
in HFpEF.
Two Types of WRF: Transient Versus Persistent
WRF
From our study, severity of WRF increased as renal function at
admission worsened, with more patients with persistent WRF
among those with lower GFR. Transient WRF occurs in those
with derangements in hemodynamics and neurohormones
during acute HF, which may include interaction with diuretics
or other theoretically reversible factors. On the other hand,
persistent WRF may occur from insults related to coexisting
comorbidities and aspects of the HF disease process itself
that are irreversible.21
The question of the effect of transient WRF remains
controversial. Krishnamoorthy et al showed that transient
WRF was associated with a higher risk of 90-day mortality,22
whereas Aronson et al23 reported that patients hospitalized
for HF with transient WRF did not have signiﬁcantly increased
mortality at 6 months postdischarge. In our study, in terms of
postdischarge short- and long-term outcomes, transient WRF
was an equivalent risk factor to persistent WRF. This
discrepancy may be partially attributed to the various
deﬁnitions of WRF and the outcomes of each study. Because
we deﬁned transient WRF as the recovery of renal function
during hospitalization,24 those with a slower recovery (ie,
those who show recovered renal function at outpatient follow-
up) could have been categorized into the persistent WRF
group, thereby diluting the pure effect of persistent WRF.
Table 9. Effect of Persistent and Transient WRF on 1-Year Follow-up Mortality
HR 95% CI P Value
Total population
WRF vs no WRF Unadjusted 2.16 1.88 to 2.48 <0.001
Adjusted 1.44 1.19 to 1.75 <0.001
Transient WRF vs no WRF Unadjusted 1.98 1.71 to 2.30 <0.001
Adjusted 1.35 1.09 to 1.67 0.006
Persistent WRF vs Transient WRF Unadjusted 1.27 1.09 to 1.48 0.003
Adjusted 1.17 0.95 to 1.44 0.150
HFrEF
WRF vs no WRF Unadjusted 2.09 1.74 to 2.51 <0.001
Adjusted 1.35 1.06 to 1.71 0.014
Transient WRF vs no WRF Unadjusted 1.88 1.53 to 2.30 <0.001
Adjusted 1.32 1.02 to 1.71 0.038
Persistent WRF vs Transient WRF Unadjusted 1.33 1.09 to 1.64 0.006
Adjusted 1.14 0.89 to 1.46 0.290
HFpEF
WRF vs no WRF Unadjusted 2.17 1.64 to 2.88 <0.001
Adjusted 1.54 1.08 to 2.18 0.016
Transient WRF vs no WRF Unadjusted 2.06 1.52 to 2.80 <0.001
Adjusted 1.50 1.03 to 2.20 0.034
Persistent WRF vsTransient WRF Unadjusted 1.19 0.84 to 1.69 0.322
Adjusted 1.14 0.75 to 1.72 0.538
CI indicates conﬁdence interval; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; WRF, worsening renal function.
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Further studies using universal deﬁnitions are mandatory to
investigate the effect of transient WRF on outcomes in
patients with acute HF.
Study Limitations
There are several limitations in this study. First, although
we applied the widely used deﬁnition of WRF, this deﬁnition
has intrinsic limits. Increase in creatinine cannot directly
reﬂect GFR, and it also depends strongly on the renal
function at admission. Additionally, regarding that we
deﬁned transient and persistent WRF by the creatinine
level during admission, some patients might have been
misclassiﬁed, according to the baseline creatinine level of
an individual. Furthermore, according to the time point of
the initial laboratory test, the initial creatinine level might
not have been the actual baseline level, and therefore some
patients with WRF may have been missed. Second, given
that this study was based on a registry cohort, it is subject
to various biases. Although our study results prove the
strong association between WRF and poor clinical out-
comes, the observational nature of our study also limits the
interpretation of the causal relationship between WRF and
clinical outcomes.
Conclusions
WRF was present in 55% of patients in the KorAHF registry.
Incidence of WRF increased as renal function at admission
decreased and was higher in patients with HFrEF than in
those with HFpEF. Predictors of WRF were similar in both HF
types. WRF was a prognostic factor of adverse in-hospital and
long-term outcomes, with a larger effect size in HFpEF
compared with HFrEF. Regardless of the degree of WRF,
transient and persistent WRF seem to be equivalent risk
factors.
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